Ayed, Ayed O. http://orcid.org/0000-0002-3233-7877
Chiappella, Annalisa
Pederson, Levi http://orcid.org/0000-0001-5902-8882
Laplant, Betsy R.
Congiu, Angela Giovanna
Gaidano, Gianluca
Spina, Michele
Re, Alessandro
Cavallo, Federica
Musuraca, Gerardo
Macon, William R.
Witzig, Thomas
Vitolo, Umberto
Nowakowski, Grzegorz S.
Article History
Received: 28 August 2017
Revised: 18 May 2018
Accepted: 25 May 2018
First Online: 26 June 2018
Institutional review board committee approval
: The two phase 2 trials from which the data were collected have been approved by the local institutional review board or ethics committee of each participating site. All research involving human subjects was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all patients participating in the clinical trials.
: AC: advisory board: Celgene; honoraria for lectures: Amgen, Celgene, Janssen, Nanostring, Pfizer, Roche, Teva. GG: consultancy: Roche, Karyopharm, Morphosys, Gilead, Janssen, Novartis; honoraria: Roche, Karyopharm, Morphosys, Gilead, Janssen, Novartis; speakers bureau: Roche, Gilead, Janssen, Novartis. MS: advisory board: Teva, Mundipharma; speaker fees: Teva, Mundipharma. FC: honoraria: Celgene, Onyx, Janssen. UV: advisory board: Roche, Celgene, Janssen; honoraria for lectures: Roche, Celgene, Takeda, Gilead, Janssen, Mundipharma; research funding: Roche, Celgene. GN: consultancy: Bayer; research funding: Bayer, Celgene, Morphosys. A.O.A., L.P., B.R.L., A.G.C., A.R., G.M., W.R.M., and T.W.: declare no conflict of interest.